Alterity Therapeutics (ATHE) Non Operating Investment Income (2010 - 2015)

Alterity Therapeutics' (ATHE) quarterly Non Operating Investment Income came in at $51.1 in Q4 2015, up 100.93% quarter-over-quarter from -$5488.0 in Q4 2010.

Alterity Therapeutics (ATHE) Non Operating Investment Income (2010 - 2015) Analysis & Trends

Alterity Therapeutics' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $51.1 for Q4 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alterity Therapeutics 29.68 Bn 29.68 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2015 51.10
Dec 31, 2015 51.10
Dec 31, 2010 -5,488.00
Dec 31, 2010 -5,488.00